10.06.14
David E. I. Pyott, CEO of Allergan Inc., has resigned his position as board member of Edwards Lifesciences Corporation. He said the reason for his resignation was so that he could devote more time leading the Irvine, Calif.-based pharmaceuticals company best known for its product Botox, used to treat neurological muscle disorders, and is also used cosmetically. Allergan is currently facing a $53 billion takeover bid from Canadian company Valeant Pharmaceuticals International Inc.
"The board and I are truly appreciative of David's service and commitment to Edwards during the last 14 years," said Michael A. Mussallem, Edwards' chairman and CEO. "David's extensive global experience in leadership roles at innovative health and nutrition companies made him a valuable resource for our company. He has been a trusted partner and brought important expertise to Edwards in delivering novel therapies to address the needs of patients. We wish him the best and thank him for the significant role he has played in Edwards' growth and success."
Pyott joined Edwards' board of directors in 2000, when Edwards was established as an independent, publicly-held corporation.
Edwards develops technology for heart valves and hemodynamic monitoring.
"The board and I are truly appreciative of David's service and commitment to Edwards during the last 14 years," said Michael A. Mussallem, Edwards' chairman and CEO. "David's extensive global experience in leadership roles at innovative health and nutrition companies made him a valuable resource for our company. He has been a trusted partner and brought important expertise to Edwards in delivering novel therapies to address the needs of patients. We wish him the best and thank him for the significant role he has played in Edwards' growth and success."
Pyott joined Edwards' board of directors in 2000, when Edwards was established as an independent, publicly-held corporation.
Edwards develops technology for heart valves and hemodynamic monitoring.